Search Results - "Rubio Pérez, J."

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer by González-Martín, Antonio, Pothuri, Bhavana, Vergote, Ignace, DePont Christensen, René, Graybill, Whitney, Mirza, Mansoor R, McCormick, Colleen, Lorusso, Domenica, Hoskins, Paul, Freyer, Gilles, Baumann, Klaus, Jardon, Kris, Redondo, Andrés, Moore, Richard G, Vulsteke, Christof, O’Cearbhaill, Roisin E, Lund, Bente, Backes, Floor, Barretina-Ginesta, Pilar, Haggerty, Ashley F, Rubio-Pérez, Maria J, Shahin, Mark S, Mangili, Giorgia, Bradley, William H, Bruchim, Ilan, Sun, Kaiming, Malinowska, Izabela A, Li, Yong, Gupta, Divya, Monk, Bradley J

“…Patients with newly diagnosed advanced ovarian cancer were randomly assigned to receive daily niraparib, a PARP inhibitor, or placebo as maintenance therapy…”
Get full text

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial by González-Martín, Antonio, Desauw, Christophe, Heitz, Florian, Cropet, Claire, Gargiulo, Piera, Berger, Regina, Ochi, Hiroyuki, Vergote, Ignace, Colombo, Nicoletta, Mirza, Mansoor R., Tazi, Youssef, Canzler, Ulrich, Zamagni, Claudio, Guerra-Alia, Eva M., Levaché, Charles B., Marmé, Frederik, Bazan, Fernando, de Gregorio, Nikolaus, Dohollou, Nadine, Fasching, Peter A., Scambia, Giovanni, Rubio-Pérez, María J., Milenkova, Tsveta, Costan, Cristina, Pautier, Patricia, Ray-Coquard, Isabelle

“…Background: PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab…”
Get full text

Dostarlimab for the treatment of endometrium cancer and other solid tumors by Rubio-Pérez, J, Hernández, R, Hernández, T, Doger, B, Casado, V, Moreno, V

“…The use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely…”
Get full text

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer by Vergote, Ignace, Ray-Coquard, Isabelle, Anderson, Daniel M., Cantuaria, Guilherme, Colombo, Nicoletta, Garnier-Tixidre, Claire, Gilbert, Lucy, Harter, Philipp, Hettle, Robert, Lorusso, Domenica, Mäenpää, Johanna, Marth, Christian, Matsumoto, Koji, Ouwens, Mario, Poveda, Andrés, Raspagliesi, Francesco, Rhodes, Kirsty, Rubio Pérez, María J., Shapira-Frommer, Ronnie, Shikama, Ayumi, Sikorska, Magdalena, Moore, Kathleen, DiSilvestro, Paul

“…In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate…”
Get full text

Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients by Morillas-Ruiz, J.M, Rubio-Perez, J.M, Albaladejo, M.D, Zafrilla, P, Parra, S, Vidal-Guevara, M.L

“…Abstract Background A large body of evidence supports a role of oxidative stress in Alzheimer disease (AD) and in cerebrovascular disease. Blood levels of…”
Get full text

Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre by Arjona-Sánchez, Álvaro, Muñoz-Casares, Francisco C., Rufián-Peña, Sebastián, Díaz-Nieto, Rafael, Casado-Adam, Ángela, Rubio-Pérez, María J., Ortega-Salas, Rosa

“…Background Pseudomyxoma peritonei (PMP) is a rare, slowly progressive disease whose prognosis depends primarily on the completeness of cytoreduction. The value…”
Get full text

When to think about pediatric congenital pseudoarthrosis of the clavicle? Presentation of 2 cases by Justich Zabala, Pablo R, Giniger Vidal, Rodolfo P, Rubio Pérez, María J, Guirao Pérez, José, Salcedo Canovas, César

“…The congenital pseudoarthrosis of the clavicle is a rare and benign malformation, characterized by the absence of the middle third of the clavicle. It is…”
Get full text

First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial by Ho, A., Garcia-Consuegra, A., Saro, J., Sauer, A., Cristiani, S., Brophy, F.E., Streets, S., Norry, E., Gillison, M., Charlson, J., Bover, M., Zugazagoitia, J., Calvo, E., Ugidos, L., Bruixola, G., Garcia, V. Moreno, Hong, D.S., Rubio-Pérez, J., Aggen, D.H.

“…ADP-A2M4CD8 is an autologous CD4+ and CD8+ T-cell therapy under investigation for treatment of advanced cancers in human leukocyte antigen (HLA)-A*02–eligible…”
Get full text

Serum cytokine profile in Alzheimer's disease patients after ingestion of an antioxidant beverage by Rubio-Perez, J M, Morillas-Ruiz, J M

“…The major neuropathologic hallmarks in Alzheimer's disease (AD) consist of neuronal cell loss in selected brain regions, as well as deposition of extracellular…”
Get more information

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis by Poveda, A., Lheureux, S., Colombo, N., Cibula, D., Lindemann, K., Weberpals, J., Bjurberg, M., Oaknin, A., Sikorska, M., González-Martín, A., Madry, R., Pérez, M.J. Rubio, Ledermann, J., Davidson, R., Blakeley, C., Bennett, J., Barnicle, A., Škof, E.

“…The phase IIIb OPINION trial (NCT03402841) investigated olaparib maintenance monotherapy in patients without a deleterious or suspected deleterious germline…”
Get full text

1691P Thromboembolic disease and immunotherapy in lung cancer by Garay, D. Fernandez, Boluda, N. Blaya, Pérez, J. Rubio, Morán, L. Ortega, Castro, J. Brenes, Lage, Y., Lavin, D. Cacho, Rubio, C. Guirao, Moreno, J. Bosque, Fernandez de Soignie, A.M. Martin, Lobo de Mena, M., Portero, B. Obispo, Garrido, M.C. Rosa, Puig, C. Font, Martín, A. Muñoz, Cánovas, M. Sánchez

Get full text

1688P Impact of immunotherapy on the risk of thromboembolic disease in patients with melanoma by Garay, D. Fernandez, Boluda, N. Blaya, Morán, L. Ortega, Benoit-Perejón, J.Z., Colomo, L. Jiménez, Lobo de Mena, M., Verduguez, T. Quintanar, Blanco, A.B. Rupérez, Fernandez de Soignie, A.M. Martin, Pérez, J. Rubio, Puig, C. Font, Portero, B. Obispo, Rubio, C. Guirao, Moreno, J. Bosque, Garrido, M.C. Rosa, Martín, A. Muñoz, Cánovas, M. Sánchez

Get full text

The Type of Fat Ingested at Breakfast Influences the Plasma Lipid Profile of Postmenopausal Women by Morillas-Ruiz, J. M., Delgado-Alarcon, J. M., Rubio-Perez, Jose Miguel, Albaladejo Oton, M. D.

“…To assess whether the type of fat ingested at breakfast can modify the plasma lipid profile and other cardiovascular risk variables in postmenopausal women at…”
Get full text

PO-87 Comparison of different clinical risk assessment models (RAMs) in ambulatory cancer patients receiving chemotherapy from the Oncothromb-02 study by Muñoz Martín, A., Ruiz Zamorano, M., Cárdenas Yebra, A., Ortega Morán, L., Ferrer Pérez, A.I., Rupérez Blanco, A.B., Rubio Pérez, J., Martínez-Galán, J., Font-Puig, C., Fernández Pérez, I., Pachón Olmos, V., Martínez de Castro, E., Quintanar Verdúgez, T., López, S., Rubio Castellón, V., Martínez-Pérez, A., Seguí, E., García Escobar, X., Salgado, M., Salas Pérez-Rasilla, E., Soria Fernández, J.M.

Get full text

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line by Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D’Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A.

“…Background This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall…”
Get full text

HyperlynX: A Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and Radiotherapy in Patients with Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck by Saba, N.F., Sukari, A., Forget, F., Popovtzer, A., Perez, J. Rubio, Park, J.H., Yang, M.H., Sato, M., Kuipers, M., Ito, R., Salmio, S.

“…The current standard of care for patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is cisplatin 100 mg/m2 every…”
Get full text

102P Clinical analysis of patients with different KRAS mutations in NSCLC: Different entities analyzed by NGS by Rubio Perez, J., Fernández Ochoa, M., Villalba Cuesta, P.L., Avedillo Ruidiaz, M., Rojo, F., Domine Gomez, M.

Get full text

1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN) by Riess, J.W., Cohen, E., Spicer, J., Shaw, P.H., Rubio Perez, J., Medina Rodríguez, L., Chaney, M.F., O'Neill, S., Pedersen, A.W., McDowell, D., Ehrnrooth, E., Garrido Lopez, P.

Get full text

2149P Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO) by Mateo, F.J. Pelegrín, Verduguez, T. Quintanar, Brilhante, D., Arias, A. Ferrández, Cardozo, A.R., Martinez de Castro, E., Munoz-Langa, J., Vazquez, E.M. Brozos, Gomez de Tejada, M. Biosca, Portero, B.O., Diaz, E. Gallardo, Perez, J. Rubio, Perez, I. Fernandez, Escobar, I. Garcia, Garcia-Adrian, S., Crespo, J.A. Santiago, Nogueira, L.R., Lopez, G. Benitez, Fonseca, P. Jimenez, Martin, A.J. Munoz

Get full text

2083P Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort by Lozano, R. Martín, Palma, M., Gonzalez, A. Rodriguez, Perez, J. Rubio, Perez, I. Fernandez, Escobar, I. Garcia, Adrian, S. Garcia, Crespo, J.A. Santiago, PedRoche, C. Diaz, Rebollo, M.T. Antonio, Morales, M.J. Ortiz, García, M.E. Guirao, del Prado, P. Martinez, De Herreros, M. Garcia, Porta-Balanya, R., Covela, M., Morán, L. Ortega, de Castro, E. Martinez, Segura, P. Pérez, Martin, A.J. Munoz

Get full text